Barclays lowered the firm’s price target on CVS Health (CVS) to $75 from $82 and keeps an Overweight rating on the shares. The firm rebased its 2024 earnings estimates lower and contemplated the slope of a recovery from here.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS: